6,678 trials
Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Number of Flare Events Per Time of Exposure to Study Medication — 0.54; 0.93 flare events per month — p=<0.0001
Hepatitis B
Primary: Number of Participants With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Specific Cut-off Values — 72; 71; 64 participants
Asthma
Primary: Mean Change From Baseline at Endpoint in Morning Peak Expiration Flow (PEF) for Intent-to-Treat Population — 26.4; 3.6 L/min — p=<0.001
Tachycardia, Ventricular · Ventricular Fibrillation
Primary: Efficacy of Anti Tachycardia Pacing (ATP) Therapy to Terminate Fast Ventricular Tachycardia (With Cycle Length of 240ms-320msec) — 64.9; 69.7 Percentage of FVT episodes…
Hepatitis B
Primary: Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations — 87.6; 43.8; 143.4; 34.4 mIU/mL
Essential Hypertension
Primary: Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy) — 38 Participants
Meningococcal Infections · Meningitis
Primary: Percentage of Participants With ≥ 4-Fold Rise in Antibody Titers — 85; 61; 61; 76 Percentage of participants
Diabetic Ketoacidosis
Primary: Number of Hypoglycemia Episodes After the Transition Period From Intravenous Insulin to Subcutaneous Insulin Between 2 Treatment Groups — 8; 26 number of hypoglycemia…
Ethmoid Sinusitis · Rhinosinusitis
Primary: Number of Participants With Adhesion as Measured by the Synechia (Adhesion) Scale — 14; 13; 4; 5 Participants
Hyperglycemia · Diabetes
Primary: Percentage of Blood Glucose Values Between 80 - 140 — 43; 35; 48 percentage of blood glucose values
Irritable Colon
Primary: Left Colon Mucosal Blood Flow (MBF) — 125.6; 117.5; 130.7; 121.6 ml per minute per 100 grams of tissue — p=0.131
Chronic Obstructive Pulmonary Disease · Bronchitis · Emphysema
Primary: Time-normalized Area Under the Change From Study Baseline Curve for Forced Expiratory Volume in One Second (FEV1) Over 24 Hours (nAUC0-24B) — 0.104; 0.080; 0.221 Liters…
Influenza
Primary: Percentage of Participants With Solicited Injection Site or Systemic Reaction(s) After Fluzone® Vaccination — 78; 38; 78; 30 Percentage of Participants
Attention Deficit Hyperactivity Disorder
Primary: Change From Pre-dose (0 hr [Hour]) on the Swanson, Kotkin, Agler, M-Flynn & Pelham (SKAMP) Rating Scale Combined Score at 0.5 Hour During the 8- Hour Laboratory…
Influenza
Primary: Geometric Mean Titer (GMT) of Hemagglutination Inhibition Antibodies Pre-vaccination and 14 Days Post-vaccination — 5.0; 8.2; 187.8; 95.1 Titer